GlassScriptPhysician profile
Rajeev Sharma
NPI 1326342924
$1,709.96
in general payments reported to CMS, 2019-2025
20 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.33 · 2023: $184 · 2024: $867 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $308.92 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $284.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $194.07 | 2023-2025 | Korlym |
| Medtronic, INC. | $139.55 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $105.87 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $102.19 | 2024-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $87.95 | 2023-2025 | |
| Abbott Laboratories | $74.99 | 2024-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $57.43 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.37 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Cequr Corporation | $45.49 | 2024-2025 | Cequr Simplicity |
| Dexcom, INC. | $40.32 | 2024 | Dexcom G6 Transmitter |
| Chiesi USA, INC. | $34.46 | 2024 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $34.00 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $32.65 | 2023-2024 | Farxiga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $32.59 | 2024-2025 | Recorlev |
| E.R. Squibb & Sons, L.L.C. | $26.44 | 2025 | Cobenfy |
| Alvogen INC | $23.81 | 2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $18.72 | 2025 | |
| Abbvie INC. | $15.86 | 2023 | Synthroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.